Tissue Repository for Biomedical Research

This study is a tissue repository that collects and stores biological samples (biospecimens) and health information from people with conditions like Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, and Amyloidosis. The goal is to provide these samples to researchers to help them discover new treatments, ways to diagnose diseases, and prevention methods. You may be asked to provide a tissue sample, most likely from a blood draw, and potentially complete a survey. The study aims to collect biospecimens and clinical data over 10 years. The current recruitment status is unclear, and the study plans to enroll up to 20,000 participants aged 18 to 85 years.

Study design
This is an observational study planning to enroll up to 20,000 participants. It is not a treatment study but rather a collection of samples for future research.
What's involved
You may be asked to provide a tissue sample, most likely from a blood draw (up to 100mL for health conditions, 60mL for exceptive conditions, or 180mL for controls), and potentially complete a survey.
Compensation
Not stated in the trial record.
Follow-up
Biospecimen and clinical data collection will be measured at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

UNKNOWN
Not specifiedAges 18–85Observational
Sanguine Biosciences
~20,000 participants
Updated 2024-05-07 on ClinicalTrials.gov
What's tested:Specimen sample

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biospecimen & Clinical Data Collection
Measured over 10 years
Age-Related Macular Degeneration
Allergies
Alpha-Gal Syndrome
Alzheimer Disease
Amyloidosis
Ankylosing Spondylitis
Arthritis
Alopecia Areata
Asthma
Atopic Dermatitis
Autism
Autoimmune Hepatitis
Behcet's Disease
Beta-Thalassemia
Cancer
Celiac Disease
Kidney Diseases
COPD
Crohn Disease
Cystic Fibrosis
Diabetes
Dravet Syndrome
DMD
Fibromyalgia
Graves Disease
Thyroid Diseases
Hepatitis
Hidradenitis Suppurativa
ITP
Leukemia
ALS
Lupus or SLE
Lymphoma
Multiple Sclerosis
Myasthenia Gravis
Heart Diseases
Parkinson Disease
Pemphigus Vulgaris
Cirrhosis
Psoriasis
Schizophrenia
Scleroderma
Sickle Cell Disease
Stroke
Ulcerative Colitis
Vasculitis
Vitiligo
1 sites across 1 states
Massachusetts1
  • Houman Hemmati, MD · PRINCIPAL_INVESTIGATOR · Sanguine Biosciences

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Persons 18 to 85 years of age at the date of informed consent.
If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting.
Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.

Exclusion

Persons younger than 18 years of age or older than 85 years of age at the date of informed consent.
Receipt of blood products 30 days before the study blood draw.
Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks.
Has donated a unit of blood within the last 2 months at the date of informed consent.
  • Biospecimen & Clinical Data Collection10 years

    To collect enough biospecimens and associated clinical data to allow researchers to come to statistically relevant scientific results